Bain Capital Life Sciences

Total investments

78

Average round size

111M

Portfolio companies

48

Rounds per year

9.75

Lead investments

16

Follow on index

0.37

Exits

22

Stages of investment
Private Equity
Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Bain Capital Life Sciences appeared to be the VC, which was created in 2016. The company was established in North America in United States. The leading representative office of defined VC is situated in the Boston.

The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the most successful fund investment fields, there are Manufacturing, Health Care. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Annexon Biosciences, Rapid Micro Biosystems, Pharvaris

The overall number of key employees were 2.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Bain Capital Life Sciences, startups are often financed by Correlation Ventures, Omega Funds, Longitude Capital. The meaningful sponsors for the fund in investment in the same round are RA Capital Management, Cormorant Asset Management, Foresite Capital. In the next rounds fund is usually obtained by Samsara BioCapital, Pfizer Venture Investments, Perceptive Advisors.

The increased amount of exits for fund were in 2018. Considering the real fund results, this VC is 70 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 50 - 100 millions dollars. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. This Bain Capital Life Sciences works on 21 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually.

Show more

Investments analytics

Analytics

Total investments
78
Lead investments
16
Exits
22
Rounds per year
9.75
Follow on index
0.37
Investments by industry
  • Biotechnology (65)
  • Health Care (53)
  • Medical (33)
  • Pharmaceutical (32)
  • Therapeutics (27)
  • Show 13 more
Investments by region
  • United States (66)
  • South Korea (1)
  • Germany (4)
  • Netherlands (1)
  • Switzerland (3)
Peak activity year
2020
Number of Unicorns
2
Number of Decacorns
2
Number of Minotaurs
5

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
10
Avg. valuation at time of investment
67M
Group Appearance index
0.95
Avg. company exit year
9
Avg. multiplicator
0.88
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Areteia Therapeutics 12 Jul 2022 Biotechnology, Health Care, Life Science, Therapeutics Early Stage Venture 350M
CereVasc 13 May 2024 Biotechnology, Health Care, Medical Device Early Stage Venture 70M United States, Massachusetts, Newton
Mindesk 30 Jan 2019 Software, 3D Technology, Real Time, CAD Seed 120K United States, California, San Francisco
OKP4 01 Apr 2022 Big Data, Cryptocurrency, IT Infrastructure, Blockchain Seed Midi-Pyrenees, Toulouse, France

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.